• Academy Events

  • Pharmacologic Resolution of Inflammation as a Novel Therapeutic Approach

    Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM
    The New York Academy of Sciences

    Presented by the Biochemical Pharmacology Discussion Group

    Uncontrolled, chronic inflammation is now considered a major component of many widespread diseases, which are now well-recognized as 'inflammatory diseases.' These include arthritis, asthma, atherosclerosis and peripheral vascular disease, Alzheimer’s disease, periodontal disease and cancer. There is general agreement that inflammation is not likely to be the causative factor in these diseases, but that it plays a key role in disease progression, tissue dysfunction and ultimately organ failure. In recent years, evidence has emerged that resolution of inflammation is a biochemically active process driven by multiple chemical mediators. Elucidation of the biochemical pathways contributing to the resolution of inflammation has provided many new anti-inflammatory targets and an opportunity for resolution-based pharmacology for treatment and prevention of inflammatory diseases. This symposium reviews recent discoveries and advances in the field, and demonstrates how this work translates into new approaches and new pharmacology to treat old diseases.

    *Networking reception to follow.

    This event will also be broadcast as a webinar.

    Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker's presentation will be broadcast in full via the webinar. To access all speakers' presentations in full, we invite you to attend the live event in New York City when possible.

    Registration and Webinar Pricing

    Member $30
    Student / Postdoc Member $15
    Nonmember (Academia) $65
    Nonmember (Corporate) $85
    Nonmember (Non-profit) $65
    Nonmember (Student / Postdoc / Resident / Fellow) $45

    The Biochemical Pharmacology Discussion Group is proudly supported by

    • Merck
    • WilmerHale

    Mission Partner support for the Frontiers of Science program provided by Pfizer